Palvella Therapeutics, Inc (PVLA) - Total Assets
Based on the latest financial reports, Palvella Therapeutics, Inc (PVLA) holds total assets worth $66.94 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Palvella Therapeutics, Inc shareholders equity for net asset value and shareholders' equity analysis.
Palvella Therapeutics, Inc - Total Assets Trend (2020–2024)
This chart illustrates how Palvella Therapeutics, Inc's total assets have evolved over time, based on quarterly financial data.
Palvella Therapeutics, Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Palvella Therapeutics, Inc's total assets of $66.94 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 94.8% |
| Accounts Receivable | $2.34 Million | 2.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Palvella Therapeutics, Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PVLA stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Palvella Therapeutics, Inc's current assets represent 100.0% of total assets in 2024, an increase from 72.1% in 2020.
- Cash Position: Cash and equivalents constituted 94.8% of total assets in 2024, up from 67.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 2.7% of total assets.
Palvella Therapeutics, Inc Competitors by Total Assets
Key competitors of Palvella Therapeutics, Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Palvella Therapeutics, Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.49 | 4.82 | 2.05 |
| Quick Ratio | 6.49 | 4.82 | 2.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $56.62 Million | $16.27 Million | $30.22 Million |
Palvella Therapeutics, Inc - Advanced Valuation Insights
This section examines the relationship between Palvella Therapeutics, Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 25.08 |
| Latest Market Cap to Assets Ratio | 10.94 |
| Asset Growth Rate (YoY) | 1069.0% |
| Total Assets | $88.23 Million |
| Market Capitalization | $965.15 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Palvella Therapeutics, Inc's assets at a significant premium (10.94x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Palvella Therapeutics, Inc's assets grew by 1069.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Palvella Therapeutics, Inc (2020–2024)
The table below shows the annual total assets of Palvella Therapeutics, Inc from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $88.23 Million | +1068.97% |
| 2023-12-31 | $7.55 Million | -54.32% |
| 2022-12-31 | $16.52 Million | -89.24% |
| 2021-12-31 | $153.56 Million | +46.23% |
| 2020-12-31 | $105.01 Million | -- |
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to tr… Read more